$VEEA
VEEA INC. Stock $veea

$veea Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000121390024019042 Filed on March 01, 2024

Income Statement

Concept	2023 Q4	2023	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.013M	$3.098M	$4.074M
YoY Change	-27.03%	-23.96%	39.68%
Operating Profit		-$3.098M	-$4.074M
YoY Change		-23.96%
Interest Expense	$3.470M	$3.999M	$13.65M
YoY Change	7.43%	-70.71%	48.5%
% of Operating Profit
Other Income/Expense, Net	-$1.442M	$3.064M	$14.65M
YoY Change	-244.25%	-79.09%	59.61%
Pretax Income	$1.015M	-$34.73K	$10.58M
YoY Change	-64.29%	-100.33%	60.42%
Income Tax
% Of Pretax Income
Net Earnings	$1.015M	-$34.73K	$10.58M
YoY Change	-64.29%	-100.33%	60.42%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.09	$0.00	$0.27
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$94.70K	$94.70K	$86.40K
YoY Change	9.61%	9.61%	-19.42%
Cash & Equivalents	$94.70K
Short-Term Investments
Other Short-Term Assets	$50.85K	$50.85K	$43.63K
YoY Change	16.55%	16.55%	-87.3%
Inventory	$7.376M
Prepaid Expenses	$50.85K
Receivables
Other Receivables
Total Short-Term Assets	$145.6K	$145.6K	$130.0K
YoY Change	11.94%	11.94%	-71.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$376.7K
YoY Change
Goodwill	$4.797M
YoY Change	4.82%
Intangibles	$628.5K
YoY Change
Long-Term Investments	$35.56M	$35.56M	$323.9M
YoY Change	-89.02%	-89.02%	1.47%
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$35.56M	$35.56M	$323.9M
YoY Change	-89.02%	-89.02%	1.45%
TOTAL ASSETS
Total Short-Term Assets	$145.6K	$145.6K	$130.0K
Total Long-Term Assets	$35.56M	$35.56M	$323.9M
Total Assets	$35.70M	$35.70M	$324.0M
YoY Change	-88.98%	-88.98%	1.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.587M	$4.587M	$2.641M
YoY Change	73.71%	73.71%	150.09%
Accrued Expenses	$4.741M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$1.250M	$1.250M	$1.000M
YoY Change	25.0%	25.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.736M	$7.736M	$3.876M
YoY Change	99.6%	99.6%	231.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.643M	$1.643M	$11.55M
YoY Change	-85.77%	-85.77%	-43.72%
Total Long-Term Liabilities	$1.643M	$1.643M	$11.55M
YoY Change	-85.77%	-85.77%	-43.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.736M	$7.736M	$3.876M
Total Long-Term Liabilities	$1.643M	$1.643M	$11.55M
Total Liabilities	$9.379M	$9.379M	$15.43M
YoY Change	-39.2%	-39.2%	-28.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$15.33M
YoY Change	0.23%
Common Stock	$1.964K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.234M	$26.32M	$308.6M
YoY Change
Total Liabilities & Shareholders Equity	$35.70M	$35.70M	$324.0M
YoY Change	-88.98%	-88.98%	1.35%

Cashflow Statement

Concept	2023 Q4	2023	2022
OPERATING ACTIVITIES
Net Income	$1.015M	-$34.73K	$10.58M
YoY Change	-64.29%	-100.33%	60.42%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$353.0K	-$1.063M	-$1.021M
YoY Change	29.57%	4.1%	-52.26%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$45.00K	$293.1M	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$45.00K	$293.1M	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$292.3M	$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	400.0K	-$292.0M	1.000M
YoY Change	60.0%	-29304.36%	-99.69%
NET CHANGE
Cash From Operating Activities	-353.0K	-$1.063M	-1.021M
Cash From Investing Activities	-45.00K	$293.1M	0.000
Cash From Financing Activities	400.0K	-$292.0M	1.000M
Net Change In Cash	1.980K	$8.302K	-20.82K
YoY Change	-108.82%	-139.87%	-119.42%
FREE CASH FLOW
Cash From Operating Activities	-$353.0K	-$1.063M	-$1.021M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement		usd
CY2022	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement		usd
CY2022Q4	plmi	Deferred Underwriting Commissions Liabilities Noncurrent DeferredUnderwritingCommissionsLiabilitiesNoncurrent	11172572	usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Registrant Name EntityRegistrantName	PLUM ACQUISITION CORP. I
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity File Number EntityFileNumber	001-40218
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1577353
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2021 Fillmore St. #2089
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94115
CY2023	dei	City Area Code CityAreaCode	(415)
CY2023	dei	Local Phone Number LocalPhoneNumber	683-6773
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	55000853	usd
CY2023	ecd	Trd Arr Adoption Date TrdArrAdoptionDate	April 12, 2023
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Trd Arr Ind Name TrdArrIndName	James Lynfield
CY2023	ecd	Trd Arr Ind Title TrdArrIndTitle	Chief Operating Officer
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum llp
CY2023	dei	Auditor Location AuditorLocation	New York
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94703	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86401	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	50853	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	43631	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	145556	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	130032	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	35555976	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	323911642	usd
CY2023Q4	us-gaap	Assets Assets	35701532	usd
CY2022Q4	us-gaap	Assets Assets	324041674	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4587330	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2640756	usd
CY2023Q4	plmi	Subscription Liability Current SubscriptionLiabilityCurrent	1567406	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7736027	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3875756	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1643271	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	379217	usd
CY2023Q4	us-gaap	Liabilities Liabilities	9379298	usd
CY2022Q4	us-gaap	Liabilities Liabilities	15427545	usd
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3255593	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	31921634	shares
CY2023Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.92
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.15
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	35555976	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	323911642	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6098498	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15333039	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15298312	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-9233742	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-15297513	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35701532	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	324041674	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	3098285	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	4074437	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-3098285	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4074437	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1264054	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-8973522	usd
CY2023	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement	-308114	usd
CY2023	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement	-308114	usd
CY2023	plmi	Reduction Of Deferred Underwriter Fee Payable ReductionOfDeferredUnderwriterFeePayable	328474	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	759768	usd
CY2022	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	1000000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	4758906	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	4679040	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3063558	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14652562	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-34727	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	10578125	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-21180336	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-4695302	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	10578125	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-15297513	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	10844098	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	5898905	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1153305	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-34727	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-9233742	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-34727	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	10578125	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	4758906	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	4679040	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1264054	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-8973522	usd
CY2023	plmi	Reduction Of Deferred Underwriter Fee Payable ReductionOfDeferredUnderwriterFeePayable	328474	usd
CY2023	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement	-308114	usd
CY2023	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement	-308114	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	759768	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	7222	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-348794	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	96291	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	120000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1946574	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1584820	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1062642	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1020823	usd
CY2023	plmi	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	1140000	usd
CY2023	plmi	Proceeds From Cash Withdraw Trust Account For Redemptions ProceedsFromCashWithdrawTrustAccountForRedemptions	294254572	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	293114572	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	294254572	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1960944	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-292043628	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1000000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	8302	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-20823	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86401	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107224	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94703	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86401	usd
CY2023	plmi	Accretion Of Class A Ordinary Shares Subject To Possible Redemption AccretionOfClassAOrdinarySharesSubjectToPossibleRedemption	5898905	usd
CY2022	plmi	Accretion Of Class A Ordinary Shares Subject To Possible Redemption AccretionOfClassAOrdinarySharesSubjectToPossibleRedemption	4695302	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	1153306	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 — ORGANIZATION AND BUSINESS OPERATIONS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plum Acquisition Corp. I (the “Company” or “Plum”) was incorporated as a Cayman Islands exempted company on January 11, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company. The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. As previously reported, on November 27, 2023 The Company executed a Business Combination Agreement with Veea Inc. The Company and Veea are working toward closing their Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company had not commenced any operations. All activity for the period from January 11, 2021 (inception) through December 31, 2023 relates to the Company’s formation and the initial public offering (“IPO”), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a business combination. The Company believes it will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on investments in the Company’s Trust account and will recognize changes in the fair value of the warrant liabilities as other income (expense).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Sponsor is Plum Partners, LLC, a Delaware limited liability company (the “Sponsor”). The registration statement for the Company’s IPO was declared effective on March 15, 2021 (the “Effective Date”). On March 18, 2021, the Company consummated the initial public offering (the “Public Offering” or “IPO”) of 30,000,000 units (the “Units), at $10.00 per Unit, generating gross proceeds of $300,000,000, which is discussed in Note 3.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously with the closing of the IPO, the Company consummated the sale of 6,000,000 warrants (the “Private Placement Warrants”), at a price of $1.50 per Private Placement Warrant, which is discussed in Note 4. Each warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, generating gross proceeds of $9,000,000, which is described in Note 4.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted the underwriter a 45-day option from March 18, 2021 to purchase up to an additional 4,500,000 Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underwriter partially exercised the over-allotment option on April 14, 2021 and purchased 1,921,634 Units at $10.00 per Unit. Simultaneously with the issuance and sale of the Units on April 14, 2021, the Company consummated the private placement with the Sponsor for an aggregate of 256,218 warrants to purchase Class A Ordinary Shares for $1.50 per warrant generating total proceeds of $384,327. On April 14, 2021, $19,216,340, net of the underwriter discount, was deposited in the Company’s Trust account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A total of $19,216,340 was placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company, acting as trustee. Transaction costs of the IPO and the exercise of the over-allotment option amounted to $18,336,269 consisting of $6,384,327 of underwriting discount, $11,172,572 of deferred underwriting discount, and $779,370 of other offering costs. Of the transaction costs, $538,777 is included in transaction costs on consolidated the statements of operations and $17,797,492 is included in consolidated statements of changes in shareholders’ deficit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Following the closing of the Public Offering on March 18, 2021 and the partial exercise of the underwriter’s over-allotment option, $319,216,340 (approximately $10.00 per Unit) from the net proceeds of the sale of the Units in the Public Offering, including the proceeds from the sale of the Private Placement Warrants, was deposited in a trust account (“Trust Account”) located in the United States at Goldman Sachs, with Continental Stock Transfer & Trust Company acting as trustee, and was invested in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invests only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its taxes, if any, the proceeds from the IPO and the sale of the Private Placement Warrants will not be released from the Trust Account (1) to the Company, until the completion of our initial Business Combination, or (2) to the Public Shareholders, until the earliest of (i) the completion of the initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, subject to the limitations described herein, (ii) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Company’s amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to provide holders of its Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within the combination period or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares, and (iii) the redemption of the public shares if the Company has not consummated its Business Combination within the Combination Period, subject to applicable law. Public Shareholders who redeem their Class A ordinary shares in connection with a shareholder vote described in clause (ii) in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within the Combination Period, with respect to such Class A ordinary shares so redeemed. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Public Shareholders (as defined below).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will provide shareholders (the “Public Shareholders”) of its Class A ordinary shares, par value $0.0001, sold in the IPO (the “Public Shares”), with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) without a shareholder vote by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem all or a portion of their Public Shares upon the completion of the initial Business Combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay the Company’s taxes, if any, divided by the number of then-outstanding Public Shares, subject to certain limitations. The amount in the Trust Account is initially anticipated to be $10.00 per Public Share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These Public Shares have been classified as temporary equity upon the completion of the IPO in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company receives the approval of an ordinary resolution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company will have until June 18, 2024, to complete an initial Business Combination. However, if the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than <span style="-sec-ix-hidden: hidden-fact-69">ten</span> business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding public shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Extraordinary General Meeting and Redemption of Shares</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 15, 2023, Plum held an Extraordinary General Meeting of its Shareholders (1) to amend Plum’s amended and restated memorandum and articles of association (the “Articles”) to extend the date (the “Termination Date”) by which Plum has to consummate a business combination (the “Articles Extension”) from March 18, 2023 (the “Original Termination Date”) to June 18, 2023 (the “Articles Extension Date”) and to allow Plum, without another shareholder vote, to elect to extend the Termination Date to consummate a business combination on a monthly basis for up to nine times by an additional one month each time after the Articles Extension Date, by resolution of Plum’s board of directors if requested by the Sponsor, and upon five days’ advance notice prior to the applicable Termination Date, until March 18, 2024, or a total of up to twelve months after the Articles Extension Date, unless the closing of Plum’s initial business combination shall have occurred prior to such date (the “Extension Amendment Proposal”) and (2) to amend the Articles to eliminate from the Articles the limitation that Plum may not redeem Class A ordinary shares to the extent that such redemption would result in Plum having net tangible assets (as determined in accordance with Rule 3a 51-1(g)(1)of the Securities Exchange Act of 1934, as amended) of less than $5,000,001 (the “Redemption Limitation”) in order to allow Plum to redeem Public Shares irrespective of whether such redemption would exceed the Redemption Limitation (the “Redemption Limitation Amendment Proposal”). The shareholders of Plum approved the Extension Amendment Proposal and the Redemption Limitation Amendment Proposal at the Shareholder Meeting and on March 15, 2023, Plum filed the amendment to the Articles with the Registrar of Companies of the Cayman Islands.</span></p> <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the vote to approve the Extension Amendment Proposal, the holders of 26,693,416 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of $10.23 per share, for an aggregate redemption amount of $273,112,311.62.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sponsor, officers and directors have agreed to (i) waive their redemption rights with respect to their Founder Shares, (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of its public shares if the Company does not complete our initial Business Combination within the Combination Period or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares, (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an initial Business Combination within the Combination Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete its initial Business Combination within the prescribed time frame) and (iv) vote their Founder Shares and public shares in favor of our initial Business Combination.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 13, 2023, Plum held an Extraordinary General Meeting of its Shareholders (“September Shareholder Meeting”) (1) to amend the Articles to extend Articles Extension Termination Date from the Articles Extension Date to December 18, 2023 (the “Second Articles Extension Date”) and to allow the Company, without another shareholder vote, to elect to extend the Termination Date to consummate a business combination on a monthly basis for up to six times by an additional one month each time after the Second Articles Extension Date, by resolution of the Company’s board of directors if requested by the Sponsor, and upon five days’ advance notice prior to the applicable Termination Date, until June 18, 2024, or a total of up to nine months after the Termination Date, unless the closing of the Company’s initial business combination shall have occurred prior to such date (the “Second Extension Amendment Proposal”) and (2) to authorize a reduction in the funds held in the Trust Account to an amount equal to $20,000,000.00 (the “Trust Reduction”), which amount will be used to compulsorily redeem up to 3,228,218 Public Shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account as of two business days prior to the redemption date, including interest (which interest shall be net of taxes payable), divided by the number of then-outstanding public shares (“Trust Reduction Proposal”). The shareholders of the Company approved the Second Extension Amendment Proposal and the Trust Reduction Proposal at the Shareholder Meeting and on September 13, 2023, the Company filed the amendment to the Articles with the Registrar of Companies of the Cayman Islands.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the vote to approve the Second Extension Amendment Proposal, (i) the Sponsor, as the sole holder of Class B Ordinary Shares, voluntarily elected to convert all Class B Ordinary Shares to Class A Ordinary Shares on a one-for-one basis in accordance with the Memorandum and Articles of Association (the “Class B Conversion”) and (ii) the holders of 1,972,625 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of $10.72 per share, for an aggregate redemption amount of $21,142,260.78 (the “Redemption”). Upon completion of the Class B Conversion and the Redemption, 7,980,409 shares of Class A common stock, excluding 3,255,593 shares of Class A Ordinary Shares subject to possible redemption, and no shares of Class B common stock remain issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As approved by its stockholders at the extraordinary general meeting (the “EGM”), the “Company filed an Amended and Restated Memorandum and Articles of Association (the “A&R Charter”) on October 25, 2023, which (i) extended the date by which the Company has to consummate a business combination to December 18, 2023 and (ii) allowed the Company, without another shareholder vote, to elect to extend the Termination Date (as defined in the Proxy Statement) to consummate a business combination on a monthly basis for up to six times by an additional one month each time after December 18, 2023 (or such shorter period as necessary to comply with applicable listing requirements), by resolution of the Company’s board of directors, if requested by Plum Partners, LLC, and upon five days advance notice prior to the applicable termination date, until June 18, 2024, or a total of up to nine months after September 18, 2023, unless the closing of a business combination shall have occurred prior thereto.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An aggregate of 1,972,625 Class A ordinary shares of the Company were tendered for redemption in connection with the shareholders’ vote at the EGM.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity, Capital Resources, and Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s liquidity needs up to March 18, 2021 had been satisfied through a capital contribution from the Sponsor of $25,000 (see Note 5) for the Founder Shares. In addition, in order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors, and third parties have committed to provide the Company Working Capital Loans (see Note 5). As of December 31, 2023 and 2022, the Company had $1,000,000 outstanding under Working Capital Loans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company had $94,703 in its operating bank account and a working capital deficit $7,590,471.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Company’s assessment of going concern considerations in accordance with FASB ASC 205-40, Presentation of Financial Statements—Going Concern”, management has determined that the Company has and will continue to incur significant costs in pursuit of its acquisition plans which raises substantial doubt about the Company’s ability to continue as a going concern. Moreover, we may need to obtain additional financing either to complete our initial Business Combination or because we become obligated to redeem a significant number of our Public Shares upon consummation of our initial Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of our initial Business Combination. If we are unable to complete our initial Business Combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the Trust Accounts. In addition, following our initial Business Combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Further, management has determined that if the Company is unable to complete a Business Combination by by June 18, 2024 (the “Combination Period”), then the Company will cease all operations except for the purpose of liquidating. The date for mandatory liquidation and subsequent dissolution as well as the Company’s working capital deficit raise substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after the Combination Period. The Company intends to complete a Business Combination before the mandatory liquidation date.</span></p>
CY2023	plmi	Condition For Future Business Combination Number Of Businesses Minimum ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum	1	pure
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	19216340	usd
CY2023	plmi	Transaction Costs TransactionCosts	18336269	usd
CY2023	plmi	Sale Of Stock Underwriting Fees SaleOfStockUnderwritingFees	6384327	usd
CY2023	plmi	Sale Of Stock Other Offering Costs SaleOfStockOtherOfferingCosts	779370	usd
CY2023	plmi	Stock Issuance Costs StockIssuanceCosts	538777	usd
CY2023	plmi	Transaction Costs For Sale Of Stock TransactionCostsForSaleOfStock	17797492	usd
CY2023Q3	plmi	Interest To Pay Dissolution Expenses InterestToPayDissolutionExpenses	100000	usd
CY2023	plmi	Minimum Net Tangible Assets Upon Consummation Of Business Combination MinimumNetTangibleAssetsUponConsummationOfBusinessCombination	5000001	usd
CY2023Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	273112311.62	usd
CY2023Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	3228218	shares
CY2023	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	1972625	shares
CY2023	plmi	Working Capital Loans WorkingCapitalLoans	1000000	usd
CY2022	plmi	Working Capital Loans WorkingCapitalLoans	1000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94703	usd
CY2023Q3	us-gaap	Assets Assets	35216939	usd
CY2023Q3	plmi	Subscription Liability Net Of Debt Discount SubscriptionLiabilityNetOfDebtDiscount	1060112	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6545772	usd
CY2023Q3	us-gaap	Liabilities Liabilities	7304205	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6319277	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13504009	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-7183933	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35216939	usd
CY2023Q2	us-gaap	Assets Assets	55228382	usd
CY2023Q2	plmi	Subscription Liability Net Of Debt Discount SubscriptionLiabilityNetOfDebtDiscount	467274	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5903054	usd
CY2023Q2	us-gaap	Liabilities Liabilities	6326512	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6912413	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13165959	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-6252747	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55228382	usd
CY2023Q1	plmi	Subscription Liability Net Of Debt Discount SubscriptionLiabilityNetOfDebtDiscount	251880	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5984882	usd
CY2023Q1	us-gaap	Liabilities Liabilities	8386585	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7531767	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15718359	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-8185793	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	279013	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15322	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-338050	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	413944	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3879911	usd
	us-gaap	Net Income Loss NetIncomeLoss	1794302	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	106416	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3131354	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	2552400	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	134931	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3864589	usd
	us-gaap	Net Income Loss NetIncomeLoss	2132353	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	28515	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	733235	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-420047	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-338050	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-7183933	usd
	us-gaap	Net Income Loss NetIncomeLoss	2552400	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-6252747	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-420047	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-8185793	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	413944	usd
	us-gaap	Net Income Loss NetIncomeLoss	1794302	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	914776	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	134931	usd
	us-gaap	Net Income Loss NetIncomeLoss	2132353	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	423600	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	28515	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-420047	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	256635	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92722	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	27550	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	120272	usd
CY2023Q3	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	35096667	usd
CY2023Q3	us-gaap	Assets Assets	35216939	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3976694	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	258966	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1000000	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	250000	usd
CY2023Q3	plmi	Subscription Liability Net Of Debt Discount SubscriptionLiabilityNetOfDebtDiscount	1060112	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6545772	usd
CY2023Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	758433	usd
CY2023Q3	us-gaap	Liabilities Liabilities	7304205	usd
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	35096667	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6319277	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13504009	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-7183933	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35216939	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	353372	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-353372	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	334975	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	279013	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	629310	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15322	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-338050	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2085609	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2085609	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	379216	usd
	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement	-308114	usd
	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement	-308114	usd
	plmi	Reduction Of Deferred Underwriter Fee Payable ReductionOfDeferredUnderwriterFeePayable	328474	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	413944	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4344597	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3879911	usd
	us-gaap	Net Income Loss NetIncomeLoss	1794302	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20880	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	52885	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	73765	usd
CY2023Q2	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	55154617	usd
CY2023Q2	us-gaap	Assets Assets	55228382	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3853954	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	331826	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1000000	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	250000	usd
CY2023Q2	plmi	Subscription Liability Net Of Debt Discount SubscriptionLiabilityNetOfDebtDiscount	467274	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5903054	usd
CY2023Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	423458	usd
CY2023Q2	us-gaap	Liabilities Liabilities	6326512	usd
CY2023Q2	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.15
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	55154617	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6912413	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13165959	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-6252747	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55228382	usd
CY2023Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	578954	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-578954	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1978245	usd
CY2023Q2	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement	-633205	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	106416	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	626320	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3131354	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	2552400	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1732236	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1732236	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	44241	usd
	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement	-308114	usd
	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement	-308114	usd
	plmi	Reduction Of Deferred Underwriter Fee Payable ReductionOfDeferredUnderwriterFeePayable	328474	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	134931	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3715287	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3864589	usd
	us-gaap	Net Income Loss NetIncomeLoss	2132353	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97811	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	102980	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	200791	usd
CY2023Q1	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	54368297	usd
CY2023Q1	us-gaap	Assets Assets	54569088	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3584797	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	265000	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1000000	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	250000	usd
CY2023Q1	plmi	Subscription Liability Net Of Debt Discount SubscriptionLiabilityNetOfDebtDiscount	251880	usd
CY2023Q1	plmi	Forward Purchase Agreement Liability ForwardPurchaseAgreementLiability	633205	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5984882	usd
CY2023Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2401703	usd
CY2023Q1	us-gaap	Liabilities Liabilities	8386585	usd
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	54368296	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7531767	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15718359	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-8185793	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54569088	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1153282	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1153282	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2022486	usd
CY2023Q1	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement	325091	usd
CY2023Q1	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement	-308114	usd
CY2023Q1	plmi	Reduction Of Deferred Underwriter Fee Payable ReductionOfDeferredUnderwriterFeePayable	328474	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	28515	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3088967	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	733235	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-420047	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-15297513	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	10844098	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-3568966	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	256635	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-420047	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-8185793	usd
CY2023Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-786320	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	166966	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	2552400	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-6252747	usd
CY2023Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-1084311	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	491175	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-338050	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-7183933	usd
	us-gaap	Net Income Loss NetIncomeLoss	1794302	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4344597	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	379216	usd
	plmi	Reduction Of Deferred Underwriter Fee Payable ReductionOfDeferredUnderwriterFeePayable	328474	usd
	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement	-308114	usd
	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement	-308114	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	413944	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-16081	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-23966	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1335939	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-709623	usd
	plmi	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	1095000	usd
	plmi	Proceeds From Cash Withdraw Trust Account For Redemptions ProceedsFromCashWithdrawTrustAccountForRedemptions	294254572	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	293159572	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1560944	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	294254572	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-292443628	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	6321	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86401	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92722	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-5439596	usd
	us-gaap	Stock Issued1 StockIssued1	914776	usd
	us-gaap	Net Income Loss NetIncomeLoss	2132353	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3715287	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	44241	usd
	plmi	Reduction Of Deferred Underwriter Fee Payable ReductionOfDeferredUnderwriterFeePayable	328474	usd
	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement	-308114	usd
	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement	-308114	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	134931	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	9254	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-96826	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1213199	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-431465	usd
	plmi	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	640000	usd
	plmi	Proceeds From Cash Withdraw Trust Account For Redemptions ProceedsFromCashWithdrawTrustAccountForRedemptions	273112312	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	272472312	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	755944	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	273112312	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-272106368	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-65521	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86401	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20880	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-4355287	usd
	us-gaap	Stock Issued1 StockIssued1	423601	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-420047	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3088967	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2022486	usd
CY2023Q1	plmi	Reduction Of Deferred Underwriter Fee Payable ReductionOfDeferredUnderwriterFeePayable	328474	usd
CY2023Q1	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement	-308114	usd
CY2023Q1	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement	325091	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	28515	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	59349	usd
CY2023Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-30000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	944041	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-238590	usd
CY2023Q1	plmi	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	480000	usd
CY2023Q1	plmi	Proceeds From Cash Withdraw Trust Account For Redemptions ProceedsFromCashWithdrawTrustAccountForRedemptions	273112312	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	272632312	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	480000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	273112312	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-272382312	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11410	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86401	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97811	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-3568966	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	256635	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these consolidated financial statements is the determination of the fair value of the subscription and forward purchase agreements and warrants liabilities. Such estimates may be subject to change as more current information becomes available and accordingly, the actual results could differ significantly from those estimates.</span></p>
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	35555976	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	323911642	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Credit Risk</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Derivative Credit Risk Valuation Adjustment Derivative Liabilities DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities	2500000	usd
CY2023	plmi	Price Threshold Of Newly Issued Stock To Cause Adjustment Of Exercise Warrant Price PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice	9.2
CY2023	plmi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Percentage ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1Percentage	1.80	pure
CY2023Q4	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	340000	usd
CY2023Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	71956	shares
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.5
CY2023Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	15	usd
CY2023Q4	us-gaap	Other Commitment OtherCommitment	750000	usd
CY2023Q4	us-gaap	Shares Issued SharesIssued	74695	shares
CY2023Q4	plmi	Subscription Share Per Share SubscriptionSharePerShare	12.5
CY2023Q4	us-gaap	Sponsor Fees SponsorFees	800000	usd
CY2023Q4	plmi	Investor Paid To Sponsor InvestorPaidToSponsor	249975	usd
CY2023Q4	plmi	Investor Paid To Sponsor InvestorPaidToSponsor	250000	usd
CY2023	plmi	Working Capitalfor Sponsor WorkingCapitalforSponsor	2359975	usd
CY2023Q4	us-gaap	Shares Issued SharesIssued	1341140	shares
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	120000	usd
CY2023	plmi	Number Of Days After The Closing Of The Initial Business Combination To File With The Sec NumberOfDaysAfterTheClosingOfTheInitialBusinessCombinationToFileWithTheSec	P20D
CY2023	plmi	Number Of Days After The Closing Of The Initial Business Combination For Registration Statement To Be Effective NumberOfDaysAfterTheClosingOfTheInitialBusinessCombinationForRegistrationStatementToBeEffective	P60D
CY2023	plmi	Effective Day For Registration Statement To Be Effective EffectiveDayForRegistrationStatementToBeEffective	P60D
CY2023	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	(A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (as defined below) less the exercise price of the warrants by (y) the fair market value and (B) 0.361. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent.
CY2023	plmi	Effective Days Of Lock Up Period EffectiveDaysOfLockUpPeriod	P30D
CY2023Q4	plmi	Deferred Underwriting Commissions Payable DeferredUnderwritingCommissionsPayable	11172572	usd
CY2023Q1	plmi	Deferred Underwriting Discount DeferredUnderwritingDiscount	11172572	usd
CY2023Q4	plmi	Maximum Threshold Reimbursement Of Attorney Fees By Sponsor MaximumThresholdReimbursementOfAttorneyFeesBySponsor	5000	usd
CY2023	plmi	Final Amount Of Sponsor Capital FinalAmountOfSponsorCapital	160000	usd
CY2023Q3	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	1090000	usd
CY2023Q3	us-gaap	Members Capital MembersCapital	750000	usd
CY2023	plmi	Business Combination Event Description Of Shares Allotment Criteria To Investors BusinessCombinationEventDescriptionOfSharesAllotmentCriteriaToInvestors	1 Class A ordinary share for each $10 of the Capital Calls
CY2023Q3	us-gaap	Withdrawal From Contract Holders Funds WithdrawalFromContractHoldersFunds	750000	usd
CY2023Q4	plmi	Investor Paid To Sponsor InvestorPaidToSponsor	249975	usd
CY2023Q4	plmi	Investor Paid To Sponsor InvestorPaidToSponsor	250000	usd
CY2023	plmi	Working Capitalfor Sponsor WorkingCapitalforSponsor	2359975	usd
CY2023Q4	us-gaap	Shares Issued SharesIssued	1341140	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3255593	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	31921634	shares
CY2023	plmi	Founder Shares Forfeited Shares FounderSharesForfeitedShares	644591	shares
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of the Class A ordinary shares and holders of the Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders, except as required by law.
CY2023	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	one-to-one
CY2022Q4	plmi	Subscription Liability Current SubscriptionLiabilityCurrent		usd
CY2023Q4	plmi	Deferred Underwriting Commissions Liabilities Noncurrent DeferredUnderwritingCommissionsLiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment		usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
CY2023	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination		usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022	plmi	Reduction Of Deferred Underwriter Fee Payable ReductionOfDeferredUnderwriterFeePayable		usd
CY2022	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement		usd
CY2022	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement		usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
CY2022	plmi	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount		usd
CY2022	plmi	Proceeds From Cash Withdraw Trust Account For Redemptions ProceedsFromCashWithdrawTrustAccountForRedemptions		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2023Q3	plmi	Redeemable Period Of Public Share RedeemablePeriodOfPublicShare	P10D
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet		usd
CY2023Q3	plmi	Subscription Liability Current SubscriptionLiabilityCurrent		usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet		usd
CY2023Q2	plmi	Subscription Liability Current SubscriptionLiabilityCurrent		usd
CY2023Q1	plmi	Subscription Liability Current SubscriptionLiabilityCurrent		usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet		usd
CY2023Q3	plmi	Subscription Liability Current SubscriptionLiabilityCurrent		usd
CY2023Q3	plmi	Deferred Underwriting Commissions Liabilities Noncurrent DeferredUnderwritingCommissionsLiabilitiesNoncurrent		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet		usd
CY2023Q2	plmi	Subscription Liability Current SubscriptionLiabilityCurrent		usd
CY2023Q2	plmi	Deferred Underwriting Commissions Liabilities Noncurrent DeferredUnderwritingCommissionsLiabilitiesNoncurrent		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q1	plmi	Subscription Liability Current SubscriptionLiabilityCurrent		usd
CY2023Q1	plmi	Deferred Underwriting Commissions Liabilities Noncurrent DeferredUnderwritingCommissionsLiabilitiesNoncurrent		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q3	plmi	Change In Fair Value Of Subscription Purchase Agreement ChangeInFairValueOfSubscriptionPurchaseAgreement		usd
	plmi	Change In Fair Value Of Subscription Purchase Agreement ChangeInFairValueOfSubscriptionPurchaseAgreement		usd
CY2023Q2	plmi	Change In Fair Value Of Subscription Purchase Agreement ChangeInFairValueOfSubscriptionPurchaseAgreement		usd
	plmi	Change In Fair Value Of Subscription Purchase Agreement ChangeInFairValueOfSubscriptionPurchaseAgreement		usd
CY2023Q1	plmi	Change In Fair Value Of Subscription Purchase Agreement ChangeInFairValueOfSubscriptionPurchaseAgreement		usd
CY2023Q3	plmi	Change In Fair Value Of Subscription Purchase Agreement ChangeInFairValueOfSubscriptionPurchaseAgreement		usd
CY2023Q3	plmi	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement		usd
CY2023Q3	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement		usd
CY2023Q3	plmi	Reduction Of Deferred Underwriter Fee Payable ReductionOfDeferredUnderwriterFeePayable		usd
	plmi	Change In Fair Value Of Subscription Purchase Agreement ChangeInFairValueOfSubscriptionPurchaseAgreement		usd
CY2023Q2	plmi	Change In Fair Value Of Subscription Purchase Agreement ChangeInFairValueOfSubscriptionPurchaseAgreement		usd
CY2023Q2	plmi	Issuance Of Forward Purchase Agreement IssuanceOfForwardPurchaseAgreement		usd
CY2023Q2	plmi	Reduction Of Deferred Underwriter Fee Payable ReductionOfDeferredUnderwriterFeePayable		usd
	plmi	Change In Fair Value Of Subscription Purchase Agreement ChangeInFairValueOfSubscriptionPurchaseAgreement		usd
CY2023Q1	plmi	Change In Fair Value Of Subscription Purchase Agreement ChangeInFairValueOfSubscriptionPurchaseAgreement		usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment		usd
CY2023Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment		usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment		usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2023	plmi	Investments Maturity Period InvestmentsMaturityPeriod	P3M
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001840317

Files In Submission

Name	View Source	Status
0001213900-24-019042-index-headers.html	Edgar Link	pending
0001213900-24-019042-index.html	Edgar Link	pending
0001213900-24-019042.txt	Edgar Link	pending
0001213900-24-019042-xbrl.zip	Edgar Link	pending
ea0200011-10k_plumacq1.htm	Edgar Link	pending
ea0200011ex24_plumacq1.htm	Edgar Link	pending
ea0200011ex31-1_plumacq1.htm	Edgar Link	pending
ea0200011ex31-2_plumacq1.htm	Edgar Link	pending
ea0200011ex32-1_plumacq1.htm	Edgar Link	pending
ea0200011ex32-2_plumacq1.htm	Edgar Link	pending
ea0200011ex4-2_plumacq1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ea0200011-10k_plumacq1_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plmi-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
plmi-20231231_cal.xml	Edgar Link	unprocessable
plmi-20231231_def.xml	Edgar Link	unprocessable
plmi-20231231_lab.xml	Edgar Link	unprocessable
plmi-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VEEA
VEEA INC. Stock $veea

2023 Q4 Form 10-K Financial Statement

#000121390024019042 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VEEA VEEA INC. Stock $veea

2023 Q4 Form 10-K Financial Statement

#000121390024019042 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VEEA
VEEA INC. Stock $veea